NCT01068652 - Effect of Different Insulin Administrations, All in Combination With Metformin, on Glycaemic Control in Subjects With Type 2 Diabetes Inadequately Controlled by Oral Anti-diabetic Drugs | Biotech Hunter

Enrollment

403

Participants

Timeline

Start Date

March 31, 2010

Primary Completion Date

May 31, 2012

Study Completion Date

May 31, 2012

Conditions

DiabetesDiabetes Mellitus, Type 2

Interventions

DRUG

insulin detemir

Initial dose of 0.1 U/kg once daily, injected s.c. (under the skin).

DRUG

insulin aspart

Pending evaluation of HbA1c every 3 months, insulin aspart was added to the insulin detemir treatment (up to three does daily, injected s.c. (under the skin)

DRUG

biphasic insulin aspart 30

Initial dose of 0.1 U/kg once daily, injected s.c. (under the skin). Pending evaluation of HbA1c every 3 months, the dose will intensified up to 3 doses daily

DRUG

metformin

1000-2000 mg/day in combination with insulin treatment

Trial Locations (19)

1053

Novo Nordisk Investigational Site, Tunisia

1812

Novo Nordisk Investigational Site, Johannesburg

1900

Novo Nordisk Investigational Site, Vaderbijlpark

2146

Novo Nordisk Investigational Site, Sandton

4170

Novo Nordisk Investigational Site, Durban

4450

Novo Nordisk Investigational Site, Durban

6014

Novo Nordisk Investigational Site, Port Elizabeth

7945

Novo Nordisk Investigational Site, Cape Town

8301

Novo Nordisk Investigational Site, Kimberly

16000

Novo Nordisk Investigational Site, Algiers

19000

Novo Nordisk Investigational Site, Sétif

20000

Novo Nordisk Investigational Site, Casablanca

21131

Novo Nordisk Investigational Site, Alexandria

22000

Novo Nordisk Investigational Site, Sidi Bel Abbes

25000

Novo Nordisk Investigational Site, Constantine

31000

Novo Nordisk Investigational Site, Oran

46000

Novo Nordisk Investigational Site, Ain Témouchent

0002

Novo Nordisk Investigational Site, Pretoria

0083

Novo Nordisk Investigational Site, Pretoria